Description

Better Safety & Tolerability
• Well tolerated by patients of all age group
• Found to cause minimum adverse events Better than Co-annoxiclav
• In treatment of Sinusitis Oral Cefpodoxime found to be better compared to Co-amoxiclav

In
• Sinusitis
• Pharyngitis & Tonsillitis
• Acute Otitis Media
• Pneumonia & Bronchitis
• Skin & Soft Tissue Infections
• Urinary Tract Infections

Results with Better Efficacy & Safety